Ikena Oncology (IKNA) Rises 11.74% on August 5

Equities Staff  |

Ikena Oncology Inc (NASDAQ: IKNA) shares climbed 11.74%, or $0.64 per share, as on 11:58:09 est today. After Opening the Day at $5.51, 32,782 shares of Ikena Oncology have been traded today and the stock has moved between $6.09 and $5.43.  

Already this year the company has a YTD change of 55.66%.

Ikena Oncology anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on Ikena Oncology visit the company profile.

About Ikena Oncology Inc

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.

To get more information on Ikena Oncology Inc and to follow the company's latest updates, you can visit the company's profile page here: Ikena Oncology Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content